^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Mantle Cell Lymphoma |
| Drug: | Rituxan (rituximab) (CD20 inhibitor) + Brukinsa (zanubrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
05/11/2023
Excerpt:
Mantle Cell Lymphoma….MAINTENANCE AFTER HDT/ASCR OR AGGRESSIVE INDUCTION THERAPY….Covalent BTKi x 2 years (category 2A for ibrutinib; category 2B for acalabrutinib or zanubrutinib) + rituximab every 8 weeks x 3 y (category 1 for rituximab following HDT/ASCR)
